| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shawn Zheng Kai Tan, Yasin Temel, Ariel Yovela Chan, Andrea Tsz Ching Mok, Jose Angelo Udal Perucho, Arjan Blokland, Luca Aquili, Wei Ling Lim, Lee Wei Li. Serotonergic treatment normalizes midbrain dopaminergic neuron increase after periaqueductal gray stimulation. Brain structure & function. vol 225. issue 7. 2021-07-06. PMID:32594260. |
in this study, we further analysed our previous data on the effects of escitalopram (a selective serotonin reuptake inhibitor, ssri) and buspirone (a 5-ht1a receptor partial agonist) on dlpag-induced anticipatory fear behaviour in a rat model using freezing as a measure. |
2021-07-06 |
2023-08-13 |
rat |
| Irina P Butkevich, Viktor A Mikhailenko, Elena A Vershinin. Neonatal pain modulates in adolescent rats the antinociceptive effects of fluoxetine and buspirone administrated to their depressive dams during gestation. Canadian journal of physiology and pharmacology. vol 99. issue 6. 2021-06-22. PMID:33186073. |
previously, we have shown that the administration of a selective serotonin reuptake inhibitor fluoxetine or a 5-ht1a receptor agonist buspirone to stressed rats during gestation causes in the offspring alleviation of formalin-induced pain, strengthened by prenatal stress. |
2021-06-22 |
2023-08-13 |
rat |
| Sergio Vegas-Suárez, Clarissa Anna Pisanò, Catalina Requejo, Harkaitz Bengoetxea, Jose Vicente Lafuente, Michele Morari, Cristina Miguelez, Luisa Uged. 6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata. British journal of pharmacology. vol 177. issue 17. 2021-06-21. PMID:32464686. |
buspirone (5-ht |
2021-06-21 |
2023-08-13 |
Not clear |
| Natalia Malikowska-Racia, Piotr Popik, Kinga Sała. Behavioral effects of buspirone in a mouse model of posttraumatic stress disorder. Behavioural brain research. vol 381. 2021-05-26. PMID:31765726. |
buspirone presents a unique profile of action, which involves activation of 5-ht |
2021-05-26 |
2023-08-13 |
mouse |
| Sergey S Panteleev, Ivan B Sivachenko, Olga A Lyubashin. The Buspirone-dependent Abdominal Pain Transmission Within the Nucleus Tractus Solitarius in the Rat. Neuroscience. vol 452. 2021-05-14. PMID:33248152. |
buspirone, a partial agonist of the 5-ht |
2021-05-14 |
2023-08-13 |
rat |
| Tomiki Sumiyosh. Cognitive enhancement in schizophrenia by buspirone: Role of serotonin Schizophrenia research. vol 215. 2021-01-18. PMID:31648843. |
cognitive enhancement in schizophrenia by buspirone: role of serotonin |
2021-01-18 |
2023-08-13 |
Not clear |
| Amir Garakani, James W Murrough, Rafael C Freire, Robyn P Thom, Kaitlyn Larkin, Frank D Buono, Dan V Iosifesc. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers in psychiatry. vol 11. 2021-01-12. PMID:33424664. |
this review's first aim is to summarize current pharmacological treatments (both approved and off-label) for panic disorder (pd), generalized anxiety disorder (gad), social anxiety disorder (sad), and specific phobias (sp), including selective serotonin reuptake inhibitors (ssris), serotonin norepinephrine reuptake inhibitors (snris), azapirones (e.g., buspirone), mixed antidepressants (e.g., mirtazapine), antipsychotics, antihistamines (e.g., hydroxyzine), alpha- and beta-adrenergic medications (e.g., propranolol, clonidine), and gabaergic medications (benzodiazepines, pregabalin, and gabapentin). |
2021-01-12 |
2023-08-13 |
Not clear |
| Konstantinos Denaxas, Spyros D Ladas, George P Karamanoli. Evaluation and management of esophageal manifestations in systemic sclerosis. Annals of gastroenterology. vol 31. issue 2. 2020-10-01. PMID:29507463. |
buspirone, a 5-hydroxytryptamine 1a receptor agonist, could be a putative therapeutic option, as it was found to exert a significant beneficial effect in ssc patients with esophageal involvement. |
2020-10-01 |
2023-08-13 |
Not clear |
| Man Jin, Yali Mo, Kaisheng Ye, Mingxian Chen, Yi Liu, Cao H. Efficacy of serotonin receptor agonists in the treatment of functional dyspepsia: a meta-analysis. Archives of medical science : AMS. vol 15. issue 1. 2020-10-01. PMID:30697251. |
functional dyspepsia (fd) is typically treated with serotonin receptor (5-ht) agonists such as cisapride, mosapride, tegaserod and tandospirone citrate. |
2020-10-01 |
2023-08-13 |
Not clear |
| Irina P Butkevich, Viktor A Mikhailenko, Elena A Vershinina, Gordon A Bar. Differences Between the Prenatal Effects of Fluoxetine or Buspirone Alone or in Combination on Pain and Affective Behaviors in Prenatally Stressed Male and Female Rats. Frontiers in behavioral neuroscience. vol 13. 2020-10-01. PMID:31244623. |
the selective serotonin reuptake inhibitor fluoxetine and the 5-ht1a receptor agonist buspirone are used to treat depression and anxiety. |
2020-10-01 |
2023-08-13 |
rat |
| Tac. Functional Dyspepsia: Impaired Fundic Accommodation. Current treatment options in gastroenterology. vol 3. issue 4. 2020-09-30. PMID:11096589. |
small or preliminary studies suggest some benefit from buspirone or selective serotonin reuptake inhibitors (ssris). |
2020-09-30 |
2023-08-12 |
Not clear |
| Irina P Butkevich, Viktor A Mikhailenko, Elena A Vershinina, Anna M Aloisi, Gordon A Bar. Long-Term Effects of Chronic Buspirone during Adolescence Reduce the Adverse Influences of Neonatal Inflammatory Pain and Stress on Adaptive Behavior in Adult Male Rats. Frontiers in behavioral neuroscience. vol 11. 2020-09-30. PMID:28184190. |
we tested whether these alterations have long-lasting effects and if those effects can be improved by the 5-hydroxytryptamine 1a (5-ht1a) receptor agonist buspirone injected chronically during the adolescent period. |
2020-09-30 |
2023-08-13 |
rat |
| Yann Develle, Hugues Leblon. Biphasic Effect of Buspirone on the H-Reflex in Acute Spinal Decerebrated Mice. Frontiers in cellular neuroscience. vol 13. 2020-09-28. PMID:32009904. |
buspirone, a partial serotonin receptor agonist (5-ht |
2020-09-28 |
2023-08-13 |
mouse |
| Young-Min Par. The Hypothesis on the Prediction of Treatment Response with Buspirone Augmentation along with Serotonergic Antidepressant in Patients with Major Depressive Disorder Using Loudness Dependence of Auditory Evoked Potentials: Two Cases and Review of the Literature for Evidence. Psychiatry investigation. vol 17. issue 3. 2020-09-28. PMID:32151126. |
some researchers assume that the antidepressant boosting effect of buspirone is revealed under a poop-out state, which means a phenomenon where some patients having an initial response to an antidepressant may worsen or not improve any more even though they continue treatment because of serotonin depletion. |
2020-09-28 |
2023-08-13 |
Not clear |
| Young-Min Par. The Hypothesis on the Prediction of Treatment Response with Buspirone Augmentation along with Serotonergic Antidepressant in Patients with Major Depressive Disorder Using Loudness Dependence of Auditory Evoked Potentials: Two Cases and Review of the Literature for Evidence. Psychiatry investigation. vol 17. issue 3. 2020-09-28. PMID:32151126. |
thus ldaep will be a biological marker for prediction of treatment response with buspirone augmentation with ssri because it can measure central serotonergic activity such as serotonin depletion. |
2020-09-28 |
2023-08-13 |
Not clear |
| Anna Czopek, Adam Bucki, Marcin Kołaczkowski, Agnieszka Zagórska, Marcin Drop, Maciej Pawłowski, Agata Siwek, Monika Głuch-Lutwin, Elżbieta Pękala, Alicja Chrzanowska, Marta Struga, Anna Partyka, Anna Wesołowsk. Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability. Bioorganic & medicinal chemistry. vol 27. issue 18. 2020-09-17. PMID:31383628. |
on the basis of the structures of serotonin modulators or drugs (nan-190, buspirone, aripiprazole) and phosphodiesterase 4 (pde4) inhibitors (rolipram, ro-20-1724), a series of novel multitarget 5-arylidenehydantoin derivatives with arylpiperazine fragment was synthesized. |
2020-09-17 |
2023-08-13 |
Not clear |
| Ting-Ren Chen, Hui-Chuan Huang, Jer-Hwa Hsu, Wen-Chen Ouyang, Kuan-Chia Li. Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis. Journal of psychiatric research. vol 118. 2020-09-08. PMID:31494377. |
the results showed that all pharmacological treatments except for serotonin modulators and second-generation antipsychotics had greater effects than placebo: norepinephrine-dopamine reuptake inhibitors (standardized mean difference (smd) -1.84, 95% credible interval -3.05 to -0.62), noradrenergic and specific serotonergic antidepressants (-0.91, -1.62 to -0.20), melatonergic receptor agonists (-0.68, -1.15 to -0.21), selective serotonin reuptake inhibitors (ssris; -0.67, -0.90 to -0.43), azapirones (-0.58, -1.00 to -0.17), anticonvulsants (-0.56, -0.85 to -0.28), serotonin-norepinephrine reuptake inhibitors (snris; -0.54, -0.79 to -0.30), and benzodiazepines (bzds; -0.40, -0.65 to -0.15). |
2020-09-08 |
2023-08-13 |
human |
| Winberg, Nilsso. Multiple high-affinity binding sites for The Journal of experimental biology. vol 199. issue Pt 11. 2019-11-20. PMID:9320352. |
8oh-dpat was found to interact with three [3h]5-ht binding sites, whereas buspirone, tfmpp, spiperone and mianserin all distinguish two sites. |
2019-11-20 |
2023-08-12 |
Not clear |
| Winberg, Nilsso. Multiple high-affinity binding sites for The Journal of experimental biology. vol 199. issue Pt 11. 2019-11-20. PMID:9320352. |
in the presence of 300 nmol l-1 buspirone, 8oh-dpat and mianserin distinguished two [3h]5-ht binding sites, whereas spiperone interacted with only one. |
2019-11-20 |
2023-08-12 |
Not clear |
| M.A. Nader, S. Hoffmann, S. Gleeson, J.E. Barret. Further characterization of the discriminative stimulus effects of buspirone using monoamine agonists and antagonists in the pigeon. Behavioural pharmacology. vol 1. issue 1. 2019-11-20. PMID:11175387. |
buspirone (0.3-10.0 mg/kg), the serotonin 1a (5-ht(1a)) agonist 8-oh-dpat (0.1-1mg/kg), the buspirone analog bmy 7378 (3.0-5.6mg/kg), the mixed 5-ht(1a/1b) agonist ru 24969 (3.0-10.0mg/kg) and the 5-ht(1a) agonist spiroxatrine (0.1-1.0mg/kg) occasioned at least 80% buspirone-appropriate responding in all subjects tested. |
2019-11-20 |
2023-08-12 |
human |